Cognitive impairment in obese patients: a pilot study. correction possibilities

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Obesity is a risk factor for cognitive impairment (CI) that has a significant impact on quality of life in patients.

Objective. To study the frequency and nature of CI in obese patients.

Subjects and methods. The study involved 51 obese patients and 28 healthy normal-weighted volunteers matched for age, gender, and level of education. Cognitive functions were assessed using the MoCa test and the Frontal Assessment Battery (FAB) scale.

Results. The median MoCA scores were 28 (27; 29) in the normal weight group and 25 (25; 27) in obese patients; the differences between the groups were statistically significant (p < 0.05). The median total FAB score in both groups was 18 (17; 18) and had no significant differences (p > 0.05).

Conclusion. The findings may suggest that the carbohydrate metabolism is associated with the risk of CI in obese patients, since obesity is related to a number of metabolic and hemodynamic disorders. The MoCa test proved to be a more sensitive cognitive screening test for mild CI in obese patients. Phytopreparations "Femo-Klim" and "Nervo-Vit" can be recommended for women with estrogen deficiency and obesity, as they contribute to the normalization of estrogen levels and weight loss, as well as contribute to the improvement of cognitive functions and psychological state. The drug "Eromax" is recommended for the correction of obesity and cognitive disorders in men associated with low testosterone levels.

Full Text

Restricted Access

About the authors

I. Gatskikh

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: potupchik_tatyana@mail.ru

Candidate of Medical Sciences

Russian Federation, Krasnoyarsk

T. Potupchik

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru

Candidate of Medical Sciences

Russian Federation, Krasnoyarsk

T. Shalda

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru
Russian Federation, Krasnoyarsk

References

  1. Alferova V.I., Mustafina S.V. Prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and metabolism. 2022;19(1):96-105. (in Russ.). doi: 10.14341/omet12809
  2. Matveeva M.V., Samoilova Yu.G., Zhukova N.G. Obesity and cognitive dysfunction. Obesity and metabolism. 2016; 3: 3–8 (in Russ.). doi: 10.14341/OMET201633-8
  3. Chugunova Yu.V., Chumakova G.A., Ermolin P.A. et al. The effect of visceral obesity on cognitive functions in patients undergoing coronary artery bypass grafting. Russian Journal of Cardiology. 2016; 4: 19–24 (in Russ.). doi: 10.15829/1560-4071-2016-4-19-24
  4. Chumakova G.A., Veselovskaya N.G., Gritsenko O.V. et al. Metabolic syndrome: complex and unresolved problems. Russian Journal of Cardiology. 2014; 3: 63–71 (in Russ.). doi: 10.15829/1560-4071-2014-3-63-71
  5. Obesity and overweight Fact sheet N311. [Electronic resource]. URL: http://www.who.int/mediacentre/factsheets/fs311/ru/
  6. Gatskikh I.V., Petrova M.M., Veselova O.F. et al. Analysis of cognitive status in patients with type 2 diabetes mellitus. Diabetes mellitus. 2018; 6: 434–40 (in Russ.). doi: 10.14341/DM7926
  7. Samoilova I.G., Rotkank M.A., Zhukova N.G. et al. Variability of glycemia in patients with type 1 diabetes mellitus: the relationship with cognitive dysfunction and the results of magnetic resonance imaging. Problems of Endocrinology. 2018; 64 (5): 286–91 (in Russ.). doi: 10.14341/probl9589
  8. Samoilova Yu.G., Rotkank M.A., Zhukova N.G. et al. Markers for cognitive impairments and variability of glycaemia in patients with type 1 diabetes mellitus. Zh Nevrol Psikhiatr Im S S Korsakova. 2018; 118 (4): 48–51 (in Russ.). doi: 10.17116/jnevro20181184148-51
  9. Yaffe K., Weston A.L., Blackwell T. et al. The Metabolic Syndrome and Development of Cognitive Impairment Among Older Women. Arch Neurol. 2009; 3: 324–8. doi: 10.1001/archneurol.2008.566
  10. Bulgakova S.V., Romanchuk N.P. Sex hormones and cognitive functions: modern data. Bulletin of Science and Practice. 2020; 6 (3): 69–95 (in Russ.). doi: 10.33619/2414-2948/52/09
  11. Mkrtumyan A.M., Egshatyan L.V. The effect of androgen deficiency on the state of carbohydrate metabolism in men. Obesity and metabolism. 2017; 14 (3): 19–24 (in Russ.). doi: 10.14341/omet2017319-24
  12. Ivanova G.P., Gorobecz L.N., Litvinov A.V. et al. The role of progesterone and its metabolites in the regulation of brain functions. Zhurnal nevrologii i psixiatrii im. S.S. Korsakova. 2018; 118 (5): 129–137. (in Russ.). doi: 10.17116/jnevro201811851129
  13. Freitas S., Simoes M., Alves L. et al. Montreal Cognitive Assessment (MoCA): Validation Study for Vascular Dementia. J Int Neuropsychol Soc. 2012; 18: 1031–40. doi: 10.1017/S135561771200077X
  14. Petrova E., Kalistratov V., Polyboyarinov P. et al. The menopause drug Femo-Klim is the best nonhormonal solution of hormonal problems. Vrach. 2019; 30 (1): 46–9 (in Russ.). doi: 10.29296/25877305-2019-01-08
  15. Khabibullina M.M., Shumilov M.D. The impact of combination therapy with Femoklim and Nervo-Vit on the psychological state of women with estrogen deficiency and metabolically healthy obesity. Vrach. 2022; 33 (6): 50–57 (in Russ.). doi: 10.29296/25877305-2022-06-09
  16. Petrova E.V., Chizh D.I., Gerczog N.A. et al. Therapeutic approaches to the correction of vasomotor and psychoemotional menopausal symptoms. Vrach. 2020; 31 (11): 37–44 (in Russ.). doi: 10.29296/25877305-2020-11-07
  17. Elistratov D.G. A medicinal product. Patent for the invention RU 2342943 C2, 10.01.2009. Application No. 2006144598/15 dated 15.12.2006. (in Russ.).
  18. Kukushkin A.V., Savel`ev V.P., Elistratov D.G. The experience of using the drug "Nervo-Vit" in the treatment of psychovegetative syndrome in patients with borderline mental disorders. In the collection: Acute disorders of cerebral circulation. Issues of diagnosis, treatment, rehabilitation. Mat-ly mezhreg. nauch.-prakt. conf. 2018; pр. 69–74 (in Russ.)
  19. Elistratov D.G., Shamilov M.D. Improvement of quality of life in menopause under the influence of Femo-Clim drug. Meditsinskaya sestra. 2022; 24 (7): 31–5 (in Russ.). doi: 10.29296/25879979-2022-07-07
  20. Zarochentseva N.V., Dzhidzhikhiia L.K. Possibilities of using klimalanin in menopausal women with vasomotor paroxysms. Russian Bulletin of Obstetrician-Gynecologist. 2012; 12 (3): 92–7 (in Russ.).
  21. Ovsyannikova T.V., Makarov I.O., Kulikov I.A. Clinical efficacy of non-hormonal methods of therapy in perimenopausal women. Obstetrics, Gynecology, Reproduction. 2013; 7 (3): 26–9 (in Russ.).
  22. Potupchik T., Veselov A., Evert L. et al. A spectrum of pharmacological effects of glycine. Vrach. 2015; 12: 14–7 (in Russ.).
  23. Lipovac M., Chedraui P., Gruenhut C. et al. Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts. Maturitas. 2010; 65 (3): 258–61. doi: 10.1016/j.maturitas.2009.10.014
  24. How licorice helps with menopause: phytoestrogens of licorice]. [Elektronnyi resurs] (in Russ.). URL: https://43simptomaklimaksa.ru/travy-i-bady/ solodka-fitoestrogeny
  25. Plaksina N.D., Simonovskaya H.Y. Possibilities of non-hormonal correction of vasomotor paroxysms in postmenopause. Gynecology. Obstetrics. A barren marriage. 2014; 19: 60–5 (in Russ.).
  26. Hellmann H., Mooney S. Vitamin B6: A Molecule for Human Health? Molecules. 2010; 15: 442–459. doi: 10.3390/molecules15010442
  27. Kukushkin A.V. The use of the phytopreparation "NERVO-VIT" in the treatment of patients with psychovegetative syndrome. Neurology/Rheumatology Special Issue. 2017; 3: 29–32 (in Russ.).
  28. Potupchik T. The possibility of using the drug FemoClim in the menopausal period. Vrach. 2019; 30 (8): 80–5 (in Russ.). doi: 10.29296/25877305-2019-08-17
  29. Balch P.A. Prescription for nutritional healing (A practical A-to-Z reference to drug-free remedies using vitamins, minerals, herbs & food supplements). 4th ed. New York. Avery. A member of Penguin Group (USA) Inc., 2006.
  30. Shikov A., Pozharitskaya O., Makarov V. et al. Effect of Leonurus cardiac oil extract in patients with arterial hypertension accompanied by anxiety and sleep disorders. Phytother Res. 2011; 25 (4): 540–3. doi: 10.1002/ptr.3292
  31. Potupchik T.V., Evert L.S., Akhmeldinova Yu.R. The use of native type 2 collagen as part of the complex agent Zhiveli Flex Active. Vrach. 2018; 29 (12): 33–7 (in Russ.). doi: 10.29296/25877305-2018-12-08
  32. Bain J. Testosterone and the aging male: to treat or not to treat? Maturitas. 2010; 66 (1): 16–22. doi: 10.1016/j.maturitas.2010.01.009
  33. Moffat S.D. Testosterone and cognitive aging in men. Neuroscience & Biobehavioral Reviews. 2014; 37: 180–93.
  34. Akimova E.V., Akimov M.Yu. Overweight in men of middle age groups: population monitoring. Vrach. 2021; 32 (2): 59–63 (in Russ.). doi: 10.29296/25877305-2021-02-11
  35. Petrova E.V., Kalistratov V.B., Poluboyarinov P.A. et al. Restoration and preservation of the male reproductive system with the help of the drug "Eromax". Materials of the 5th International Congress of Phytotherapists and Herbalists dedicated to the 100th anniversary of the Patriarch of Russian Phytotherapy K.A. Treskunov (Chernogolovka, January 28–29, 2019). (in Russ.).
  36. Elistratov D.G., Grigoriev K.I. Phytotherapy in the treatment of depressive states in adolescents. Vrach. 2022; 33 (9): 32–5 (in Russ.). DOI: 102929 6/25877305-2022-09-05
  37. Yoon D.H., Choi S.H., Yu J.H. et al. The relationship between visceral adiposity and cognitive performance in older adults. Age Ageing. 2012; 4: 456–61. doi: 10.1093/ageing/afs018

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies